Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Cytokinetics (CYTK) Leases (2020 - 2025)

Cytokinetics (CYTK) has disclosed Leases for 6 consecutive years, with $76.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases changed N/A to $76.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.0 million, a N/A change, with the full-year FY2025 number at $76.0 million, changed N/A from a year prior.
  • Leases was $76.0 million for Q4 2025 at Cytokinetics, down from $77.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $83.0 million in Q2 2021 to a low of $72.2 million in Q2 2022.
  • A 5-year average of $77.8 million and a median of $77.6 million in 2025 define the central range for Leases.
  • Peak YoY movement for Leases: skyrocketed 2401.3% in 2021, then dropped 13.07% in 2022.
  • Cytokinetics' Leases stood at $73.1 million in 2021, then grew by 13.12% to $82.7 million in 2022, then decreased by 4.53% to $79.0 million in 2023, then decreased by 3.35% to $76.3 million in 2024, then dropped by 0.48% to $76.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Leases are $76.0 million (Q4 2025), $77.6 million (Q3 2025), and $76.1 million (Q2 2025).